Clinical-stage biopharmaceutical company developing first-in-class small-molecule P2X3 receptor antagonists for chronic pain and other neurogenic disorders, including chronic cough and urologic sensory pathologies
Clinical-stage biopharmaceutical company developing first-in-class small-molecule P2X3 receptor antagonists for chronic pain and other neurogenic disorders, including chronic cough and urologic sensory pathologies. Its orally administered, non-narcotic lead candidate AF-219 targets peripheral nerves to reduce hypersensitivity, with the aim of avoiding central nervous system side effects and abuse liability.